The breast cancer drug market is poised for steady growth, with its valuation projected to reach USD 10,733.1 million in 2023. The increasing prevalence of breast cancer, coupled with the continuous evolution of novel therapies, are key factors driving this market. Early detection and advanced treatments are critical to managing the disease effectively, ensuring better patient outcomes.
Over the next decade, from 2023 to 2033, the demand for breast cancer drugs is expected to grow at a CAGR of 1.1%, culminating in a market size of approximately USD 12,012.1 million by 2033. This growth underscores the global commitment to advancing breast cancer treatment and improving survival rates.
The breast cancer drug market’s expansion reflects the ongoing investment in medical research and development, as well as the heightened awareness and emphasis on early detection. As healthcare providers and patients benefit from these advancements, the market is set to play a crucial role in the fight against breast cancer.
Get Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1246
The most frequent malignancy to affect women globally is breast cancer. According to the most recent cancer statistics, there are 1.7 million incidences of breast cancer annually. Compared to women in underdeveloped nations, women in wealthy nations like the United States, the United Kingdom, and Australia are more vulnerable.
Breast cancer is caused by a multitude of factors, such as genetic mutations (abnormal variations), age, inheritance, lifestyle, and heredity. Researchers are looking into novel imaging modalities to assess anomalies during the early stages of the disease and trying to determine the impact of genetic changes on breast cancer.
Key Takeaways:
- The global breast cancer drug market is projected to reach US$12,012.1 million by 2033, reflecting a rise from US$10,733.1 million in 2023.
- This growth is expected at a moderate compound annual growth rate (CAGR) of 1.1% throughout the forecast period.
- The rising prevalence of breast cancer and the development of novel therapies are key drivers for market expansion.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1246
Competitive Landscape:
- In August 2021, Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash.
- In June 2022, Novartis announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer.
Key Companies Profiled:
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- AstraZeneca
- Novartis International AG
- Achieve Life Science
- Bristol-Myers Squibb
- Eisai Co. Ltd
- AbbVie
- Eli Lilly & Company
- Celgene Corporation
- Merck & Co.
- Amgen Plc.
- Celldex Therapeutics
- Biocon Genzyme Corporation
Key Segments Covered in the Breast Cancer Drug Industry Analysis:
By Drug Class:
- SERM (Selective Estrogen-Receptor Modulators)-based
- Aromatase Inhibitors-based
- Biologic Response Modifiers-based
- Other Hormonal Therapies-based
By Distribution Channel:
- Hospital Pharmacies
- Pharmacies
- Drug Stores
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Explore In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/1246
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
